Immunome, Inc. · NASDAQ:IMNM
Immunome — Investor Presentation (January 2023)
27 slides from Immunome's investor presentation, Jan 30, 2023
Slide 1: Harnessing the Power of the Human Memory B Cell
Harnessing the Power of the Human Memory B Cell JANUARY 2023 Immunome, Inc. 665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | immunome.com Copyright © 2023 Immunome, Inc. All rights reserved.
Slide 2: Disclaimers and Forward-Looking Statements
2 Disclaimers and Forward - Looking Statements Copyright © 2023 Immunome, Inc. All rights reserved. This presentation includes certain disclosures that contain “forward - looking statements” intended to qualify for the “safe harbor” from liability established by the Private Securities Litigation Ref
Slide 3: Immunome: Three-Pronged Strategy
Powered by Human Memory B Cell Interrogation 3 Immunome: Three - Pronged Strategy Copyright © 2023 Immunome, Inc. All rights reserved. Successfully execute on AbbVie collaboration → $30M upfront → Eligible for up to: – $70M platform access payments – Per target option payments (low single digit mill
Slide 4: Strategic Discovery Collaboration with AbbVie
4 Strategic Discovery Collaboration with AbbVie Copyright © 2023 Immunome, Inc. All rights reserved. → AbbVie option to purchase worldwide rights for up to 10 novel target - antibody pairs arising from three specified tumor types → Key Financial Terms – $30M upfront payment – Eligible for additional
Slide 5: We See the Disease Through the Lens of a Memory B Cell
We See the Disease Through the Lens of a Memory B Cell Interrogate Most Educated Components of Immune Response in an Unbiased Manner at Industrial Scale 5 Copyright © 2023 Immunome, Inc. All rights reserved. Patient Ab responses point to actionable public targets 2 03 Patient responses unveil novel
Slide 6: Broad Applicability Across Therapeutic Areas
Broad Applicability Across Therapeutic Areas Unbiased Interrogation Unveils Targets & Underexplored Biology: Examples 6 Copyright © 2023 Immunome, Inc. All rights reserved. Immunology: Conserved Epitopes Identification of antibodies specific for broadly conserved epitopes, including across species I
Slide 7: Platform has Potential for Partnering Across Therapeutic Areas
7 Platform has Potential for Partnering Across Therapeutic Areas Copyright © 2023 Immunome, Inc. All rights reserved. → $30M Upfront → $70M Platform Milestones → Low single digit millions options payments per target → $120M/target Development and First Commercial Sale Milestones → $150M/target Sales
Slide 8: Immunome Pipeline
Immunome Pipeline Targets Identified from Authentic Human Immune Response 8 Copyright © 2023 Immunome, Inc. All rights reserved. PROGRAM POTENTIAL DISEASE OF RELEVANCE STAGE NEXT MILESTONE IMM - ONC - 01 (Anti - IL - 38) Soluble Cytokine, Immune Modulator Neutralize IL - 38; recruit and activate imm
Slide 9: Oncology Platform and Pipeline
ONCOLOGY Platform and Pipeline Copyright © 2023 Immunome, Inc. All rights reserved.
Slide 10: B cells: Critical Players in Immunity Oncology
B cells: Critical Players in Immunity Oncology 10 Copyright © 2023 Immunome, Inc. All rights reserved. → B cell infiltration more closely associated with survival than T cell presence in multiple cancers → Success of I/O therapies appears to be associated with coordinated response including B cells
Slide 11: Immunome's Discovery Engine
Immunome’s Discovery Engine Functional B Cell Interrogation to Actionable Public Targets 11 Copyright © 2023 Immunome, Inc. All rights reserved. Functional screening prioritizes patient - derived antibodies that bind to actionable public targets 0 .. 0 1 0 .. 1 1 1 0 1 0 0 0 20 40 60 80 100 Log Conc
Slide 12: Unveiling Tumor Context
Unveiling “Tumor Context” Novel Insights Into Tumor Targets and Biological Processes 12 Copyright © 2023 Immunome, Inc. All rights reserved. Immune Modulation Novel Targets Discovery Engine Extracellular Matrix Platform identifies both validated and novel actionable cancer targets Identifies targets
Slide 13: Ectopic Expression: A Unique Class of Targets
Ectopic Expression: A Unique Class of Targets with Potentially High Tumor Selectivity High Throughput Identification of Antibody - Target Pairs for Novel Modalities 13 Copyright © 2023 Immunome, Inc. All rights reserved. Highly Productive Discovery Engine for ADC and TCE Targets High Throughput Func
Slide 14: Example of an Ectopically Expressed Target as an ADC
Example of an Ectopically Expressed Target as an ADC 14 Copyright © 2023 Immunome, Inc. All rights reserved. *Immunome internal data 0 1 0 0 0 2 0 0 0 3 0 0 0 4 0 0 0 0 10 20 30 40 Raw Binding Signal S - S c o r e 17. PR121-00372 C1 1orf68 Target B Ab Highly Selective for Single Protein Target Selec
Slide 15: Recent Clinical Success and Approvals Fueling Investment in the ADC Space
Recent Clinical Success and Approvals Fueling Significant Investment in the ADC Space ADC Market: New Targets and Technologies Likely to Accelerate Growth Significant Number Of Recent ADC Approvals 15 Copyright © 2023 Immunome, Inc. All rights reserved. 1. The Antibody Society. Therapeutic monoclona
Slide 16: Novel Targets Could Drive Future ADC Market Growth
16 Novel Targets Could Drive Future ADC Market Growth Copyright © 2023 Immunome, Inc. All rights reserved. Differentiated IMNM Platform → High throughput identification of novel targets → Ectopically expressed Commercial/Phase 3 Solid Tumor ADC Programs are Still Mostly Directed at a Limited Number
Slide 17: Substantial and Sustained Early-Stage ADC Partnering Activity
Substantial and Sustained Early - Stage ADC Partnering Activity 17 Copyright © 2023 Immunome, Inc. All rights reserved. → New ADC platforms are improving clinical outcomes of ADC products, leading to several recent approvals → Large recent investments in ADC platforms expected to increase the demand
Slide 18: Oncology Lead Program IMM-ONC-01
Oncology Lead Program IMM - ONC - 01 Copyright © 2023 Immunome, Inc. All rights reserved.
Slide 19: Anti-IL-38 in Oncology
Anti - IL - 38 in Oncology Selective Immuno - oncology Therapy, IND Filing Anticipated Mid - 2023 19 Copyright © 2023 Immunome, Inc. All rights reserved. CPIs effective, but response rate is limited Cytokine - targeted therapies limited by inappropriate TME context, off - target effects, poor effica
Slide 20: IL-38 is Expressed in Multiple Tumors
IL - 38 is Expressed in Multiple Tumors 2 IHC Data Supports Transcriptional Data 3 → Tumor Versus Healthy Adjacent Tissue Expression (% of Patient Expression) → Pathology Scoring of Individual Head & Neck Cancer Patient Samples by Stage IL - 38 Expression in Solid Tumors 20 Copyright © 2023 Immunome
Slide 21: IL-38 Overexpression Inhibits Infiltration of T cells into Tumors
IL - 38 Overexpression Inhibits Infiltration of T cells into Tumors In Vivo High IL - 38 Expression is Associated with Reduced Immune Cell Infiltration* → IL - 38 high tumor samples correlate with reduced infiltration of multiple immune subsets, especially in lung, head & neck, and gastroesophageal
Slide 22: Anti-IL-38 Antibody Blocking Leads to Tumor Control in Two Tumor Models
IMM - ONC - 01 Anti IL - 38 Antibody Blocking IL - 38 Leads to Tumor Control in Two Different Tumor Models 1 22 Copyright © 2023 Immunome, Inc. All rights reserved. Demonstration of Anti - Tumor Activity (B16.F10 Model) Induction of Anti - Tumor Memory (EMT6 Model) → Immunologically cold tumor model
Slide 23: IMM-ONC-01 Program Summary
→ In vitro and in vivo preclinical research confirms antitumor activity of IMM - ONC - 01 in solid tumors as a monotherapy → Gene expression profiling of patient tumors suggest normal IL - 38 biology is co - opted by tumors of squamous origin to suppress immune infiltration → IMM - ONC - 01 exhibits
Slide 24: Financial Overview and Intellectual Property Snapshot
24 Financial Overview and Intellectual Property Snapshot Copyright © 2023 Immunome, Inc. All rights reserved. → Cash at least through 3Q 2024 → Eligible for additional platform access and option payments during the research term in the AbbVie Collaboration → Platform enables flexible business model
Slide 25: Immunome "At a Glance"
Immunome “At a Glance” Disruptive Platform Leveraging Human Immune Response 25 Copyright © 2023 Immunome, Inc. All rights reserved. Discovery Of Novel Antibody - Target Pairs → Enabled by patient memory B cell interrogation → Widely applicable across therapeutic areas → Platform uniquely suited to r
Slide 26: Experienced Management Team
Matthew Robinson, PhD Chief Technology Officer Antibody Structure Function Expert formerly at Fox Chase Cancer Center 26 Experienced Management Team Purnanand Sarma , PhD President & CEO Corleen Roche Chief Financial Officer Dennis Giesing , PhD Chief Development Officer Former CEO of Taris Biomedic
Slide 27: Board of Directors
27 Board of Directors Copyright © 2023 Immunome, Inc. All rights reserved. Michael Rapp Chairman of the Board John LaMattina , PhD Franklyn G. Prendergast, MD Michael Lefenfeld Philip Wagenheim Managing Member, Broadband Capital Investments, LLC Formerly President, Pfizer Global Research & Developme